Iconovo

Iconovo FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Iconovo (ICO.ST) as of Oct 30, 2026 is 146.99 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 112.89 % — a change of 30.21% (higher).

FCF Conversion

146.99 %

YoY

30.21%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Iconovo is 2025 146.99 % . FCF Conversion Rate (FCF/EBITDA) of Iconovo was 2024 112.89 % . It decreases by 30.21% higher compared to the previous year.

The Iconovo FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
143.97 SEK
Jan 1, 2019
182.55 SEK
Jan 1, 2020
166.55 SEK
Jan 1, 2021
141.08 SEK
Jan 1, 2022
160.32 SEK
Jan 1, 2023
134.03 SEK
Jan 1, 2024
112.89 SEK
Jan 1, 2025
146.99 SEK
The Iconovo FCF Conversion history
YEARFCF ConversionYoY
146.99 %+30.21%
112.89 %-15.78%
134.03 %-16.39%
160.32 %+13.64%
141.08 %-15.29%
166.55 %-8.77%
182.55 %+26.80%
143.97 %-124.89%
-578.32 %-422.29%
179.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Iconovo Stock analysis

What does Iconovo do? Iconovo AB generates revenue through the development, manufacturing, and supply of inhalation products. The company offers device platforms including ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices, and ICOpre, which are part of its device family. Iconovo also provides development programs for generic inhalation products based on therapeutic equivalence, as well as development for inhalation products using generic API and new chemical entity (NCE) applications. These services are targeted at pharmaceutical companies seeking to develop inhalation therapies, particularly for generic and innovative drug delivery systems. The company’s solutions include formulation, analytical testing, and documentation services tied to its device platforms. Iconovo AB’s product portfolio supports the development of pre-metered devices like ICOpre and capsule-based devices such as ICOcap, which are used in respiratory treatment applications. Its clinical trial programs, such as phase I-II trials using ICOone, cater to pharmaceutical clients requiring early-stage development support for inhalation products. Iconovo AB’s business model focuses on providing end-to-end solutions for inhalation product development, from formulation to clinical trials. The company serves pharmaceutical manufacturers who need to bring inhalation therapies to market, leveraging its device platforms and development expertise. Its offerings are structured around specific device types and development pathways, ensuring tailored support for both generic and novel inhalation product launches. Iconovo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Iconovo stock

FCF Conversion Rate (FCF/EBITDA) of Iconovo is 146.99 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Iconovo changed from 112.89 % to 146.99 %, representing a 30.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Iconovo since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Iconovo with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Iconovo

All Key Metrics — Iconovo